Novartis Q3: new drugs step up as generics squeeze Entresto
Fast growth for recently label-expanded drugs fuelled Novartis’ Q3 performance, despite headwinds from generic competition affecting more established blockbusters. Net sales …
Post
-
-
Turning bottlenecks into breakthroughs in gene therapy manufacturing
In late 2023, the first CRISPR-based gene therapy for sickle cell disease patients Casgevy, received the seal of approval from …
-
Hemab closes $157m in funding for bleeding disorder treatments
Hemab Therapeutics has concluded an oversubscribed Series C funding round, raising $157m to further develop therapies for bleeding disorders. The investment …
-
MSD receives FDA approval for Winrevair’s updated indication
MSD has received US Food and Drug Administration (FDA) approval for an updated indication of Winrevair (sotatercept-csrk) for injections of …
-
Organon CEO stands down amid contraceptive sales malpractice probe
Organon CEO Kevin Ali has stepped down from his leading position at the company, following its board’s discovery of sales …
-
Guardant and Zephyr AI pair up to advance cancer biomarker development
Guardant Health and Zephyr AI have partnered to advance the discovery of novel cancer biomarkers, as more precise tumour treatment …
-
Improving vaccine outreach and education with real-world data
Vaccines are one of the most powerful tools in global health, credited with preventing millions of deaths each year. Vaccines …
-
GSK targets Syndivia’s prostate cancer ADC in £268m buy
GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate cancer treatment, …
-
Eli Lilly buys Adverum in eye disease gene therapy punt
Eli Lilly has agreed to acquire eye disease specialist Adverum Biotechnologies, bucking a recent trend of big pharma companies deciding …
-
Excellergy eyes IgE therapy space as Xolair nears patent expiry
After bursting on the scene with a $70m Series A fundraise, Excellergy is forecasting first-in-human trials for both its lead …
-
Chugai acquires Renalys, enhancing its kidney disease portfolio
Chugai Pharmaceutical has signed a definitive stock agreement to purchase Japan-based Renalys Pharma, augmenting its kidney disease portfolio. Chugai will also …
-
Novartis agrees to buy Avidity Biosciences for $12bn
Novartis has signed an agreement for the acquisition of all outstanding shares of US-based Avidity Biosciences for $12bn in cash …
-
UK regulators seize illegal weight loss drugs amid global pricing shake-up
UK drug regulators have shut down an illicit manufacturing facility producing counterfeit glucagon-like peptide-1 receptor agonist (GLP1-RA) medications in the …
-
Dupixent stirs Sanofi’s growth as vaccine sales cool
A 26.2% increase in sales for anti-inflammatory blockbuster Dupixent (dupilumab) ensured Sanofi had a strong Q3, despite the company’s vaccine …
-
Lilly and Incyte to seek approval of alopecia JAK inhibitor in children
Eli Lilly and Incyte’s oral JAK inhibitor has shown benefit in hair regrowth in paediatric patients with severe alopecia areata. In …
